- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04998838
Stop Hep B @ Birth
Stop Hep B @ Birth: Community-Oriented Care Model for the Prevention of Mother-To-Child Transmission of Hepatitis B in Peri-Urban Yangon
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
An estimated 248 million people worldwide are chronically infected with hepatitis B virus (HBV); and 75% of them live in Asia. Mother-to-child transmission (MTCT) accounts for the majority of chronic hepatitis B infections in Southeast Asia. Elimination of MTCT of HBV is theoretically possible with a comprehensive suite of interventions that includes birth dose vaccination, hepatitis B immune globulin, and antenatal antiviral therapy (e.g., tenofovir). However, the ideal gestational age to initiate antenatal tenofovir remains undefined; and evidence is lacking for implementation strategies capable of providing cost-effective, equitable access to a comprehensive suite of interventions to prevent MTCT of HBV in low-resource settings.
Component I: Prevention of Vertical Transmission Pregnant women living in the study area will be identified and screened for hepatitis B by a network of antenatal care (ANC) providers and existing community outreach workers; HBsAg positive patients will be invited to participate in the study. Consenting participants will provide serum samples to assess eligibility for anti-viral therapy: creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, HCV, HIV. Pregnant women eligible for antiviral therapy according to WHO criteria, or who have viral load (VL) >200,000 IU/mL, will be treated with tenofovir starting at 20 weeks gestation through 4 weeks postpartum. Hospital-based delivery will be encouraged. All newborns, including those delivered at home, will receive the HBV birth dose vaccine within 24 hours of delivery, and newborns of women on tenofovir treatment will also receive Hepatitis B Immunoglobulin within 24 hours after delivery. Children will be linked to routine immunization services in Myanmar to complete their HBV vaccination series (HBV is co-formulated in a pentavalent vaccine). Maternal VL will be measured at delivery; infants will be tested for hepatitis B infection at 24-28 weeks postpartum.
Component II -- Household Screening and Treatment The household members of HBsAg positive pregnant women who consent to participate in the study will be screened for HBV-related immune status and chronic HBV infection. Non-immune individuals (HBsAb/Ag negative) will be vaccinated; HBsAg positive household members will be assessed for treatment eligibility and initiated on anti-viral therapy according to World Helath Organization guidelines. Eligible household members will also be screened every six months for hepatocellular carcinoma (HCC) by liver ulatrasound and alpha-fetoprotein levels
Qualitative Study:
In-depth interviews with approximately 30 HBsAg-positive women, 30 HBVsAg-negative women, and 20 household members of study participants will be conducted to assess barriers and facilitators related to HBV testing and treatment. Approximately 15 key-informant interviews with healthcare providers and community leaders will also be conducted. Sample size will depend on data saturation and will be adjusted based on results of data analysis during the study.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Khin Pyone Kyi, MD
- Telefonnummer: +95 9 250 022 398
- E-post: pmcthbv2018kpk@gmail.com
Studera Kontakt Backup
- Namn: Eindra Htoo, MD
- Telefonnummer: +95 9 975 477 478
- E-post: eindrahtoo@cpintl.org
Studieorter
-
-
-
Yangon, Myanmar
- Rekrytering
- BK Kee Clinic
-
Kontakt:
- Hnin Nandar Htut
- E-post: nandar@bkkeefoundation.org
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Pregnant women >= 18 years of age
- Gestational age =<34 weeks
- Test positive for HBsAg
- Live in study site area in South Dagon and Dagon Seikkan Townships, Yangon Region
- Give informed consent to participate in the study
- Newborns and household members of pregnant women enrolled in the study according to previous inclusion criteria
Exclusion Criteria:
- Alanine aminotransferase (ALT) levels >300 IU/L
For qualitative study:
Inclusion criteria
- Key informants (e.g., healthcare providers and community leaders in the study area) OR
- HBsAg+ women and their household members in the study area
- HBsAg- women and their household members in the stud area
- Give informed consent to participate in the study
- History of renal dysfunction
- CrCL < 50mL/min
- ALT>5 times the upper limit of normal (ULN)
- Evidence of decompensated cirrhosis (e.g., jaundice, ascites, history of upper gastrointestinal bleeding/esophageal varices, and hepatic encephalopathy)
- Any concomitant condition or treatment that, in view of the clinical site investigator, would contraindicate participation or satisfactory follow-up in the study HIV positive status unless 1) they are currently on additional ART therapy, or 2) their viral load is demonstrated to be <50 copies. Women who are newly diagnosed with HIV and referred to start a TDF-based regimen may be considered eligible once they have started the TDF-based regimen.
- Concurrent participation in any other clinical trial without written agreement of the study team
- Does not intend to deliver within catchment area, and/or intends to migrate before newborn follow-up is complete
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Tenofovir Disoproxil Fumerate
Pregnant women (>=20 weeks of gestation) will be treated with TDF if clinically eligible; newborns will receive birth dose vaccine (and HBIG if eligible).
Non-eligible women will be treated according to normal practices; newborns will still receive birth dose vaccine.
|
Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
Andra namn:
Treated according to normal Myanmar processes for HBV positive patients
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Vaccine within 24 hours
Tidsram: Within 24 hours of birth
|
Proportion of newborns of HBsAg positive mothers receiving HBV vaccine within 24 hours of birth
|
Within 24 hours of birth
|
Effective treatment of pregnant women
Tidsram: During pregnancy (until delivery) of each woman, average of 9 months
|
Proportions of pregnant women with chronic HBV (HBsAg positive) who are (a) linked to care (attend BK Kee Clinic for assessment of treatment eligibility); (b) complete TDF eligibility testing; (c) initiate tenofovir treatment (TDF, among those eligible); (d) adhere to TDF treatment until delivery and (e) continue treatment until 4 weeks post-partum o Low/medium/high high medication adherence are defined, respectively, as ≤6, 6-7 or 8 points on the Morisky Medication Adherence Scale (MMAS-8) |
During pregnancy (until delivery) of each woman, average of 9 months
|
Household contact screening
Tidsram: Upon identification of participating women, until the end of the project, average of 1 year
|
Proportions of adult household contacts who (a) are screened for chronic HBV infection and immunity (HBsAg/Ab); (b) are linked to care (among HBsAg positive) or vaccinated (if HBsAb negative); (c) complete appropriate testing for hepatocellular carcinoma (HCC) screening, (d) eligible for TDF treatment; (e) initiate chronic HBV treatment with TDF
|
Upon identification of participating women, until the end of the project, average of 1 year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Total screening of mothers
Tidsram: During pregnancy (until delivery) of each woman, average of 9 months
|
Proportion of pregnant women in the target population who are:
|
During pregnancy (until delivery) of each woman, average of 9 months
|
Antenatal care for HBV positive pregnant mothers
Tidsram: During pregnancy (until delivery) of each woman, average of 9 months
|
Proportions of pregnant women with chronic HBV who:
|
During pregnancy (until delivery) of each woman, average of 9 months
|
Vaccination of HBV negative pregnant mothers
Tidsram: During pregnancy (until delivery) of each woman, average of 9 months
|
Proportion of women who tested negative for HBsAg and HBsAb at baseline who complete the HBV vaccination schedule
|
During pregnancy (until delivery) of each woman, average of 9 months
|
Treatment of high viral load pregnant mothers
Tidsram: At delivery; during antenatal care testing; at 4 months postpartum, throughout the project, average of 12 months
|
Among women who had VL>200,000 IU/mL at baseline and were eligible for TDF treatment:
|
At delivery; during antenatal care testing; at 4 months postpartum, throughout the project, average of 12 months
|
Viral suppression
Tidsram: At delivery, throughout the project (one off)
|
Associations of maternal viral suppression (VL <200,000 at delivery and: baseline HBV VL, duration of exposure to TDF, and TDF adherence
|
At delivery, throughout the project (one off)
|
Mother-to-child transmission
Tidsram: At 28 weeks postpartum, throughout the project (one off)
|
Proportion of infants born to HBsAg positive mothers who
|
At 28 weeks postpartum, throughout the project (one off)
|
Household screening
Tidsram: At household screening, throughout the project (one off)
|
Among household members screened for HBsAg and HBsAb: o Prevalence of chronic infection (% HBsAg positive); and immune status (% HBsAb positive and HBsAg negative) |
At household screening, throughout the project (one off)
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Completed vaccination courses
Tidsram: Before age 1, average of 1 year
|
Proportion of infants of HBsAg positive mothers who complete HBV vaccination prior to study termination, before and after coronavirus- and coup- related delays in public vaccination program
|
Before age 1, average of 1 year
|
Proportion of pregnant women with HBsAg identified by surveillance team members
Tidsram: During pregnancy, average of 9 months
|
Proportion of pregnant women with HBsAg identified by surveillance team members
|
During pregnancy, average of 9 months
|
Timeliness of pregnancy surveillance
Tidsram: During pregnancy, average of 9 months
|
Among pregnant women identified by surveillance team members:
|
During pregnancy, average of 9 months
|
Equity of intervention
Tidsram: During pregnancy and in first year after delivery, average of 16 months
|
Distributions of select outcomes according to age, sex and axes of social disadvantage: household wealth; educational attainment; occupation; and ethnic/religious affiliation
|
During pregnancy and in first year after delivery, average of 16 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Khin Phone Kyi, MD, Myanmar Liver Foundation
- Huvudutredare: Adam K Richards, MD, University of California, Los Angeles
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Leversjukdomar
- Hepatit, Viral, Human
- Hepadnaviridae-infektioner
- DNA-virusinfektioner
- Hepatit B
- Hepatit
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Omvända transkriptashämmare
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Immunologiska faktorer
- Tenofovir
- Antikroppar
- Immunoglobuliner
- Immunglobuliner, intravenöst
- gamma-globuliner
- Rho(D) immunglobulin
Andra studie-ID-nummer
- HBV2020
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hepatit B
-
Nathan DenlingerBristol-Myers SquibbRekryteringB-cells non-Hodgkin lymfom - återkommande | Diffust stort B-cellslymfom - återkommande | Follikulärt lymfom - återkommande | Höggradigt B-cellslymfom - återkommande | Primärt mediastinalt stort B-cellslymfom - återkommande | Transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort... och andra villkorFörenta staterna
-
Northwestern UniversityNational Cancer Institute (NCI)Aktiv, inte rekryterandeDiffust stort B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Höggradigt B-cellslymfom, ej specificerat på annat sätt | T-cell/Histiocyt-rik stort B-cellslymfom | Höggradigt B-cellslymfom med MYC och BCL2 och/eller BCL6 omarrangemang | Diffust stort B-cellslymfom aktiverat... och andra villkorFörenta staterna
-
Nanfang Hospital of Southern Medical UniversityRekryteringB-cellslymfom | B-cells akut lymfoblastisk leukemi | B-cellsleukemi | B-cellslymfom refraktär | B-cellslymfom ÅterkommandeKina
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeÅterkommande diffust stort B-cellslymfom aktiverat B-cellstyp | Refraktärt diffust stort B-cellslymfom aktiverat B-cellstypFörenta staterna, Saudiarabien
-
Lapo AlinariRekryteringÅterkommande höggradigt B-cellslymfom med MYC, BCL2 och BCL6 omarrangemang | Refraktärt höggradigt B-cellslymfom med MYC, BCL2 och BCL6 omarrangemang | Återkommande höggradigt B-cellslymfom med MYC och BCL2 eller BCL6 omarrangemang | Refraktärt höggradigt B-cellslymfom med MYC och BCL2 eller... och andra villkorFörenta staterna
-
Athenex, Inc.RekryteringB-cells lymfom | CLL/SLL | ALLA, barndom | DLBCL - Diffust stort B-cellslymfom | B-cell leukemi | NHL, Återfall, Vuxen | ALL, vuxen B-cellFörenta staterna
-
Ohio State University Comprehensive Cancer CenterRekryteringDiffust stort B-cellslymfom | Höggradigt B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Diffust stort B-cellslymfom Germinalt centrum B-cellstypFörenta staterna
-
Curocell Inc.RekryteringHöggradigt B-cellslymfom | Diffust stort B-cellslymfom (DLBCL) | Primärt mediastinalt stort B-cellslymfom (PMBCL) | Transformerat follikulärt lymfom (TFL) | Refraktärt stort B-cellslymfom | Återfall av stort B-cellslymfomKorea, Republiken av
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenAktiv, inte rekryterandeÅterkommande diffust stort B-cellslymfom | Refraktärt diffust stort B-cellslymfom | CD20 positiv | Steg I diffust stort B-cellslymfom | Steg II diffust stort B-cellslymfom | Steg III Diffust stort B-cellslymfom | Steg IV Diffust stort B-cellslymfomFörenta staterna
-
National Cancer Institute (NCI)RekryteringHöggradigt B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort B-cellslymfomFörenta staterna
Kliniska prövningar på Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)
-
New Discovery LLCRekryteringViremia | Hepatit B-infektion | Kronisk infektion | Missbildning | Medfödd missbildningKina